ABVX:NASDAQ
Abivax SA
$115.95
arrow_downward
-2.94%(-3.51) 1D
$116.01
arrow_upward
+0.06% (+0.064)bedtimeAfter hours
Closed: Sep 10, 4:00:01 PM GMT-4 · USD
search
All symbols
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for ABVX...
Open
$117.80
High
$118.75
Low
$114.30
Mkt. cap
8.64B
Avg. vol.
924.42K
Volume
0.00
52-wk high
$148.83
52-wk low
$69.81
Shares outstanding
87.35M
No. of employees
80
Open
$117.80
High
$118.75
Low
$114.30
Mkt. cap
8.64B
Avg. vol.
924.42K
Volume
0.00
52-wk high
$148.83
52-wk low
$69.81
Shares outstanding
87.35M
No. of employees
80
News stories
From web sources and news partners
Benzinga
·
18 hours ago
This Amer Sports Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
Investing.com
·
19 hours ago
Goldman Sachs initiates Abivax stock coverage with buy rating
www.marketscreener.com
·
22 hours ago
Analyst calls lift stocks even as solid results come in below expectations
Profile
Abivax SA is a clinical stage biotechnology company focused on developing innovative treatments that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases.
Abivax has a program in clinical development with its lead drug candidate, obefazimod, to treat ulcerative colitis. Another program in Crohn’s disease is also in preparation and other potential inflammatory indications are being evaluated.
The company’s headquarters are based in Paris, France with a US office in Waltham, Massachusetts. Abivax’s Research and development work is conducted at its research center based in Montpellier, France. Wikipedia
About Abivax SA
CEOMarc de Garidel | Hartmut J. Ehrlich
Employees80
FoundedDec 4, 2013
Headquarters-
SectorBiotechnology
Websiteabivax.com